Change of Director's Interest Notice (JG)
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Appendix 3Y
Rule 3.19A.2
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity:
Antisense Therapeutics Limited (ASX: ANP)
ABN:
41 095 060 745
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
James Garner
Date of last notice
9 May 2023
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Date of change
8 May 2023
Note: Provide details of the circumstances giving rise to the relevant
interest.
No. of securities held prior to change
Direct
Indirect
Total
Class
Number acquired
Number disposed
+ See chapter 19 for defined terms.
Shares
-
Options
-
Fully Paid Ordinary Shares
Direct
Indirect
Total
Shares
300,000
300,000
Options
-
Direct
Indirect
Total
Shares
-
Options
-
01/01/2011
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$0.074 per share.
No. of securities held after change
Direct
Indirect
Total
Nature of change
Shares
300,000
300,000
Options
-
On-Market Trade.
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: If consideration is non-cash, provide details and
an estimated valuation
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the N/A
trade to proceed during this period?
If prior written clearance was provided, on what date was N/A
this provided?
The CFO Solution
+ See chapter 19 for defined terms.Appendix 3Y Page 201/01/2011
Share your feedback
Discover